|Bid||28.00 x 800|
|Ask||47.00 x 2200|
|Day's Range||38.39 - 39.31|
|52 Week Range||34.64 - 55.00|
|Beta (3Y Monthly)||0.59|
|PE Ratio (TTM)||210.00|
|Earnings Date||Oct 30, 2019 - Nov 4, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||52.29|
We think intelligent long term investing is the way to go. But along the way some stocks are going to perform badly...
NEW YORK , Sept. 24, 2019 /PRNewswire/ -- Pacira BioSciences Inc. (NASD: PCRX) will replace Shutterfly Inc. (NASD: SFLY) in the S&P SmallCap 600 effective prior to the open of trading on Monday, September ...
Pacira BioSciences, Inc. (PCRX), a leading provider of innovative non-opioid pain management options, today announced the appointment of Christopher J. Christie to its board of directors. Chris Christie served as the 55th Governor of the State of New Jersey from January 2010 to January 2018. “We are honored to welcome Governor Christie to the Pacira board of directors.
The company intends that these study results will provide the foundation for a supplemental New Drug Application submission to the U.S. Food and Drug Administration (FDA) seeking expansion of the EXPAREL label to include children aged six and over. “Pediatric patients—arguably our most vulnerable surgical population—urgently need opioid-free options to manage postsurgical pain. This is particularly true for children six to 12 years of age who do not have any FDA-approved local anesthetic options today,” said Dave Stack, chairman and chief executive officer of Pacira.
CEO and Chairman of Pacira Biosciences Inc (30-Year Financial, Insider Trades) David M Stack (insider trades) sold 12,849 shares of PCRX on 08/15/2019 at an average price of $39.15 a share. Continue reading...
Pacira (PCRX) delivered earnings and revenue surprises of 20.59% and 2.80%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
-- Total revenues increased 22% over prior year to $102.6 million in second quarter -- -- Conference call today at 8:30 a.m. ET -- PARSIPPANY, N.J., Aug. 08,.
PARSIPPANY, N.J., Aug. 07, 2019 -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today reported that it will present at the 2019 Wedbush Pacgrow Healthcare Conference at 12:45 PM ET.
Pacira (PCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
If you own shares in Pacira BioSciences, Inc. (NASDAQ:PCRX) then it's worth thinking about how it contributes to the...
Pacira BioSciences, Inc. (PCRX) today announced that it will report its second quarter financial results before the open of the U.S. markets on Thursday, August 8, 2019. International callers may dial 1-720-545-0035 and use the same passcode.
This morning, Durect (DRRX) announced that they submitted a full response to FDA’s Complete Response Letter for POSIMIR, which Durect received in February 2014. POSIMIR is the company’s investigational post-operative pain relief depot that utilizes the company’s patented SABER technology and is intended to deliver bupivacaine to provide three days of pain relief after surgery. As a reminder DRRX submitted an NDA ((via 505(b)(2) pathway)) to FDA for POSIMIR in April 2013.
The EMA authorizes Pacira's (PCRX) marketing application for Exparel (bupivacaine liposome injectable suspension) to treat postsurgical pain.
PARSIPPANY, N.J., June 26, 2019 -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced results of a new analysis of patients undergoing elective third molar (“wisdom.
Pacira BioSciences, Inc. (“Pacira”) (PCRX) today announced that the company’s Marketing Authorization Application (MAA) for EXPAREL® (bupivacaine liposome injectable suspension) for postsurgical analgesia was validated by the European Medicines Agency (EMA). With this validation, the Pacira application is complete and the EMA Committee for Medicinal Products for Human Use (CHMP) will now begin the review procedure with an opinion expected in the second half of 2020. “The validation of our MAA by the EMA is another major step forward in our effort to significantly expand patient access to EXPAREL-based opioid-sparing strategies,” said Dave Stack, chairman and chief executive officer of Pacira BioSciences. “We have submitted a robust dataset demonstrating the efficacy of EXPAREL in infiltration, field block, and nerve block in both placebo-controlled and active comparator studies.